Rotating PET and linear accelerator system for PET-guided radiation therapy

项目摘要 消融性放射治疗是一种非常有效的非侵入性破坏肿瘤的方法。然而，体内的肿瘤， 随着呼吸而移动，并需要为这种高剂量治疗提供精确的靶向。有各种各样的 实现肿瘤跟踪以在体内实现消融性放射治疗的技术，然而这些是 由于必要运动的复杂性和侵入性，仅限于治疗患者的少数皮损 管理技巧。因此，出现晚期疾病的患者不止几个 转移部位(如5-10个病灶)不能用消融性放射治疗。反射式医疗正在发展 第一种基于生物引导的直接实时靶向肿瘤的通用方法。利用 患者的正电子发射断层扫描(PET)，这项新技术允许连续和 自动对多个皮损进行剂量整合，使剂量升级到目标(S)并降低毒性 敏感组织。这一概念已经通过模型实验和蒙特卡罗软件进行了验证 模拟。这项建议有两个具体的目标，以减轻第一个临床开发中的关键风险 硬件原型系统。目标1将评估辐射源或直线加速器(直线加速器)的影响 系统可将PET系统放在台面上，反之亦然。目标2将同时演示 直线加速器和聚酯系统在闭合环架上的运行。这些目标的成功将使 将完成临床原型并随后实现第一个生物引导的商业化 放射治疗系统。

Project Summary Ablative radiotherapy is a very effective way to non-invasively destroy a tumor. Tumors in the body, however, move with respiration and require precise targeting for this high dose treatment. There are a variety of technologies that implement tumor tracking to achieve ablative radiotherapy in the body, however these are limited to treat just a few lesions in a patient due to the complexity and invasiveness of the necessary motion management techniques. Therefore, patients that present with later stage disease with more than a few metastatic sites (e.g. 5-10 lesions) are not treatable with ablative radiotherapy. RefleXion Medical is developing the first universal method for direct real-time targeting of tumors based on biological guidance. Utilizing positron emission tomography (PET) emissions from the patient, this new technique allows for continuous and automatic dose conformation to multiple lesions, enabling dose escalation to the target(s) and toxicity reduction to sensitive tissues. The concept has been proven with phantom experiments and monte-carlo software simulations. This proposal has two specific aims to mitigate the key risks in the development of the first clinical prototype hardware system. Aim 1 will evaluate the effects that the radiation source or linear accelerator (linac) system may have on the PET system on a bench-top, and vice-versa. Aim 2 will demonstrate simultaneous operation of the linac and PET systems on a closed-ring gantry. Success of these aims will enable the full clinical prototype to be completed and subsequent commercialization of the first biologically guided radiotherapy system.